Nicollet Investment Management Inc. Takes $897,000 Position in Moderna, Inc. $MRNA

Posted by Brian Himes on Jun 11th, 2026

Nicollet Investment Management Inc. acquired a new stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,413 shares of the company’s stock, valued at approximately $897,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. New Mexico Educational Retirement Board boosted its holdings in Moderna by 1.9% in the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after purchasing an additional 300 shares during the last quarter. Cromwell Holdings LLC grew its stake in shares of Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after buying an additional 341 shares during the period. IFP Advisors Inc increased its holdings in shares of Moderna by 5.4% during the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after buying an additional 348 shares during the last quarter. Deseret Mutual Benefit Administrators raised its position in shares of Moderna by 16.9% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock valued at $78,000 after buying an additional 382 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Moderna by 6.2% during the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,334 shares of the company’s stock valued at $241,000 after buying an additional 546 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRNA has been the subject of several analyst reports. Morgan Stanley set a $33.00 price objective on Moderna in a research report on Friday, May 1st. Barclays lifted their target price on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research report on Thursday, April 2nd. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Evercore set a $35.00 price objective on Moderna in a research report on Tuesday, February 17th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a report on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $36.60.

View Our Latest Report on MRNA

Moderna Price Performance

MRNA stock opened at $45.99 on Thursday. The business’s fifty day moving average price is $49.63 and its 200 day moving average price is $43.80. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $18.25 billion, a PE ratio of -5.64 and a beta of 1.05.

Moderna (NASDAQ:MRNA – Get Free Report) last released its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s revenue was up 260.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.52) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -6.51 EPS for the current year.

Insider Buying and Selling at Moderna

In other news, Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the transaction, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at $183,800.16. This trade represents a 70.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 71,752 shares of company stock worth $3,453,843. 10.80% of the stock is owned by company insiders.

Moderna Company Profile

(Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.